Global Losartan and Hydrochlorothiazide Tablets Market Size By Type (50 mg/ 12.5 mg, 100 mg/ 25 mg), By Application (Hospital, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Losartan and Hydrochlorothiazide Tablets Market was valued at USD 1.9 billion in 2023 and is projected to surpass USD 3.1 billion by 2031, expanding at a CAGR of 6.4% during the forecast period from 2023 to 2031. This growth is primarily driven by the rising prevalence of hypertension and related cardiovascular disorders, increased awareness about combination therapies, and favorable regulatory support for generic drug production. Losartan and Hydrochlorothiazide tablets are widely prescribed for managing high blood pressure, reducing the risk of strokes, and protecting kidney function in patients with type 2 diabetes.

Drivers:

1. Rising Prevalence of Hypertension and Cardiovascular Diseases:

The growing global burden of hypertension, particularly among aging populations and urban dwellers with sedentary lifestyles, is propelling the demand for effective antihypertensive medications like Losartan and Hydrochlorothiazide.

2. Shift Toward Combination Therapies:

Healthcare providers are increasingly favoring fixed-dose combination drugs due to improved patient compliance and better therapeutic outcomes, which is boosting market adoption.

3. Patent Expiries and Growth of Generics:

The expiration of patents for branded antihypertensive medications has opened the door for generic drug manufacturers, significantly increasing product availability and affordability across emerging markets.

Restraints:

1. Side Effects and Drug Interactions:

Losartan and Hydrochlorothiazide tablets can lead to adverse effects such as electrolyte imbalance, dizziness, and renal impairment, which can deter usage in sensitive patient groups.

2. Competition from Alternative Therapies:

The availability of other antihypertensive drug combinations and newer therapeutic options poses a challenge to market growth.

Opportunity:

1. Expansion in Emerging Markets:

Rapid urbanization, increasing healthcare investments, and awareness programs in countries such as India, Brazil, and Indonesia are creating substantial opportunities for market expansion.

2. Telemedicine and E-pharmacy Integration:

The rise of online pharmacies and telehealth consultations is making prescription medications more accessible, especially in remote areas, supporting broader market penetration.

Market by System Type Insights:

The 50 mg/12.5 mg dosage form held the largest market share in 2023, owing to its widespread prescription for newly diagnosed patients and those needing mild to moderate blood pressure control. However, the 100 mg/25 mg dosage is projected to experience robust growth due to its preference in treating patients with severe hypertension and comorbidities.

Market by End-use Insights:

The Retail Pharmacies segment dominated the market in 2023, accounting for over 45% of total revenue, driven by higher consumer accessibility and affordability. The Hospital Pharmacies segment is expected to grow significantly during the forecast period due to the rise in hospital admissions related to cardiovascular conditions and the increasing integration of combination therapy into inpatient care protocols.

Market by Regional Insights:

North America held the largest market share in 2023 due to a well-established healthcare infrastructure, high awareness of cardiovascular health, and favorable insurance coverage. However, Asia-Pacific is expected to register the fastest growth, driven by a growing middle-class population, rising hypertension prevalence, and expanding pharmaceutical manufacturing capabilities.

Competitive Scenario:

Key players in the Global Losartan and Hydrochlorothiazide Tablets Market include:

Teva Pharmaceutical Industries Ltd.

Mylan N.V. (now part of Viatris)

Sun Pharmaceutical Industries Ltd.

Lupin Limited

Torrent Pharmaceuticals Ltd.

Novartis AG

Aurobindo Pharma

Zydus Lifesciences

Glenmark Pharmaceuticals Ltd.

Hikma Pharmaceuticals PLC

These companies are focusing on expanding their generic product portfolios, improving production scalability, and entering strategic partnerships to increase their global footprint.

Scope of Work – Global Losartan and Hydrochlorothiazide Tablets Market

Report Metric Details

Market Size (2023) USD 1.9 Billion

Projected Market Size (2031) USD 3.1 Billion

CAGR (2023–2031) 6.4%

Market Segments By Dosage Type (50 mg/12.5 mg, 100 mg/25 mg), By End-use (Retail Pharmacies, Hospital Pharmacies)

Growth Drivers Rising hypertension prevalence, Generic drug expansion, Combination therapy demand

Opportunities Expansion in emerging markets, E-pharmacy integration

Key Market Developments:

2023: Teva Pharmaceuticals expanded its U.S. generic cardiovascular drug portfolio by launching a new variant of Losartan and Hydrochlorothiazide tablets.

2024: Sun Pharma initiated Phase IV trials in Asia to evaluate long-term adherence and outcomes in patients using combination antihypertensives.

2025: Lupin announced a strategic partnership with a regional health authority in Africa to supply affordable antihypertensive medication through public healthcare channels.

FAQs:

1. What is the current market size of the Global Losartan and Hydrochlorothiazide Tablets Market?

The market was valued at USD 1.9 billion in 2023.

2. What is the major growth driver of the Global Losartan and Hydrochlorothiazide Tablets Market?

The rising prevalence of hypertension and the shift toward fixed-dose combination therapies are key drivers.

3. Which is the largest region during the forecast period in the Global Losartan and Hydrochlorothiazide Tablets Market?

North America held the largest share in 2023, while Asia-Pacific is expected to grow the fastest through 2031.

4. Which segment accounted for the largest market share in Global Losartan and Hydrochlorothiazide Tablets Market?

The 50 mg/12.5 mg dosage segment accounted for the largest share in 2023.

5. Who are the key market players in the Global Losartan and Hydrochlorothiazide Tablets Market?

Key players include Teva Pharmaceutical, Mylan (Viatris), Sun Pharma, Lupin, Torrent, and others.